Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-121Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination (DCVax-L) in glioblastoma: breakthrough or fata morgana?
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-12-23 / Neuro Oncol 2022 Dec;Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial Carcinoma /von 2022-12-12 / Front Immunol 2022;13:1080947Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-12-04 / Cancer Med 2023 Mar;12(6):7207-7221Immunotherapy for the treatment of pediatric brain tumors: a narrative review
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2022-12-01 / Transl Pediatr 2022 Dec;11(12):2040-2056Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects
/in International Publications, Newcastle Disease Virus /von 2022-11-26 / J Clin Med 2022 Nov;11(23)Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK Veröffentlichungen /von 2022-10-27 / Int J Mol Sci 2022 Oct;23(21)Commentary on „Systematic review about complementary medical hyperthermia in oncology“ by Liebl et al
/in Hyperthermia, International Publications /von 2022-10-14 / Clin Exp Med 2022 Nov;22(4):667-672Cellular Immunotherapy for Medulloblastoma
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2022-10-11 / Neuro Oncol 2022 Oct;
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
- Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
- Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy